Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FimH is a bacterial adhesin protein found at the tip of type 1 fimbriae in Escherichia coli. It specifically binds to mannose residues on host cell glycoproteins and is a major determinant of E. coli’s ability to attach to and colonize epithelial surfaces, notably in the urinary tract. FimH plays a critical role in the pathogenesis of urinary tract infections and contributes to biofilm formation, making it a validated target for anti-adhesion drugs and vaccines. The FimH adhesin features a double-domain structure: a mannose-binding lectin domain and a pilin domain that anchors it to the fimbria. Mutations in FimH can alter binding characteristics and enhance virulence. Targeted pharmacological inhibition or immunization against FimH disrupts bacterial adhesion and is under investigation for preventing E. coli infections
Competitive inhibition (occupying the mannose-binding pocket to prevent adhesion); Allosteric inhibition (stabilizing non-adhesive FimH conformations); Vaccine-induced antibody response targeting FimH
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FimH adhesin (Escherichia coli) (FimH).